Related Experiment Videos
In vitro cytotoxicity of imidazolyl-1,3,5-triazine derivatives
S Yaguchi1, Y Izumisawa, M Sato
1Research Laboratory, Zenyaku Kogyo Co., Ltd., Tokyo, Japan.
Abstract:
We examined in vitro cytotoxic activity of imidazolyl-1,3,5-triazine derivatives using human breast cancer cell lines (MCF-7, R-27, T-47D and ZR-75-1) and murine leukemia cell line (P388). The percentage of viable cells was determined by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazorium bromide (MTT) assay. Hexamethylmelamine (HMM), a 1,3,5-triazine derivative has previously been recognized as an antitumor agent effective against lung, ovarian and breast cancer, but failed to show a significant cytotoxic activity in the present study. In contrast, four imidazolyl-1,3,5-triazine derivatives, 2-(1-imidazolyl)-4,6-bis(morpholino)-1,3,5-triazine, 2-(1-imidazolyl)-4-morpholino-6-(3-thiazolidinyl)-1,3,5-triazine, 2-(4-cyano-4-phenylpiperidino)-4-(1-imidazolyl)-6-morpholino-1,3,5-triaz ine and 2-(1-imidazolyl)-4-(N-methyl-N-phenylamino)-6-morpholino-1,3,5-triazine showed cytotoxic activity for most cell lines, which was significantly greater than the activity of hydroxymethylpentamethylmelamine (HMPMM), a major metabolite of HMM.
Insights
New imidazolyl-1,3,5-triazine derivatives show significant in vitro cytotoxic activity against human breast and murine leukemia cancer cell lines. These compounds demonstrate greater efficacy than hexamethylmelamine (HMM) and its metabolite HMPMM.
Area of Science:
- Medicinal Chemistry
- Pharmacology
- Cancer Research
Background:
- 1,3,5-triazine derivatives, including hexamethylmelamine (HMM), have been investigated for antitumor properties.
- HMM has shown efficacy against various cancers but exhibited limited activity in this study.
- The development of novel cytotoxic agents is crucial for cancer therapy.
Purpose of the Study:
- To evaluate the in vitro cytotoxic activity of novel imidazolyl-1,3,5-triazine derivatives.
- To compare the efficacy of these derivatives against established 1,3,5-triazine compounds and their metabolites.
- To identify potential new anticancer agents for breast and leukemia cancers.
Main Methods:
- Cytotoxicity was assessed using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazorium bromide (MTT) assay.
- Human breast cancer cell lines (MCF-7, R-27, T-47D, ZR-75-1) and a murine leukemia cell line (P388) were utilized.
- The activity of four imidazolyl-1,3,5-triazine derivatives was compared to HMM and hydroxymethylpentamethylmelamine (HMPMM).
Main Results:
- Hexamethylmelamine (HMM) did not show significant cytotoxic activity in this study.
- Four imidazolyl-1,3,5-triazine derivatives exhibited notable cytotoxic effects across multiple cancer cell lines.
- The tested imidazolyl-1,3,5-triazine derivatives demonstrated significantly greater activity than HMPMM.
Conclusions:
- Imidazolyl-1,3,5-triazine derivatives represent a promising class of compounds for cancer treatment.
- These novel derivatives show superior in vitro cytotoxic potential compared to HMM and its metabolite.
- Further investigation into these compounds could lead to new therapeutic strategies for breast and leukemia cancers.